Ann R Coll Surg Engl 2007; 89: [777][778][779][780][781][782][783][784] 777 Total hip replacement (THR) is a common orthopaedic procedure that can lead to significant blood loss. Patients undergoing THR often receive allogenic red blood cell transfusion to replace blood lost in the peri-operative period. 1,2Transfusion of allogenic blood introduces several risks to the patient, including transmission of blood-borne infections, iso-immunisation, haemolytic and anaphylactic reactions. In Britain, the theoretical transmission of variant Creutzfeldt-Jacob disease has become a recent concern.Increasing awareness of the potential risks of allogenic transfusion has lead to the emergence of autologous blood transfusion. Pre-operative donation, intra-operative and postoperative cell salvage techniques have become widely used in attempts to reduce allogenic blood requirements. [3][4][5][6][7] Despite initial safety concerns regarding particulate contamination and development of coagulopathy, the retransfusion of unwashed salvaged blood has been shown to be a safe and effective alternative to allogenic transfusion. [8][9][10][11][12] Previous studies have assessed the use of postoperative re-infusion of drainage blood in patients undergoing THR. These studies included patients who had predonated autologous blood or had had blood salvage carried out intraoperatively.The benefit of postoperative drainage blood retransfusion in patients who have predonated autologous blood is not clear. Studies carried out by Rollo et al. 3 and Ayers et al. 13 indicated that the use of a postoperative retransfusion system in patients who had predonated autologous blood did not reduce their allogenic blood requirements. These findings were contradicted by Grosvenor et al.,12 who found that postoperative blood retransfusion significantly reduced the need for allogenic transfusion in patients undergoing THR whether or not they had predonated autologous blood. In the study of Grosvenor et al., The infusion of allogenic blood exposes the recipient to significant risks including the transmission of infection, anaphylactic and haemolytic reactions. The purpose of this study was to determine the effect of introducing a system to retransfuse salvaged drainage blood in patients undergoing primary THR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.